Olema Pharmaceuticals, Inc. (OLMA)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch OLMA
See up to 3 months of OLMA. The 7-day demo opens the 1M and 3M ranges and puts OLMA on your watchlist.
Start 7-day demoLatest OLMA insider trades
About Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. files with the SEC under CIK 0001750284 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
OLMA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 25,000 | $291K |
| Grant or award | 1 | 650,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
OLMA insider transactions (Form 4)
5739 Form 4 filings on record, the earliest from Nov 18, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jason O'Byrne - Officer | Grant or award | Stock Option (Right to Buy) | 650,000 | $0.00 | - | |
| Cyrus Harmon - Director | Open-market sale | Common Stock | 12,500 | $11.58 footnote F1 | $145K | |
| Cyrus Harmon - Director | Open-market sale | Common Stock | 12,500 | $11.71 footnote F2 | $146K | |
| ||||||
| BVF PARTNERS L P - Director | Grant or award | Stock Option (Right to buy) | 29,500 | $0.00 | - | |
| Cyrus Harmon | Grant or award | Stock Option (Right to Buy) | 29,500 | $0.00 | - | |
| Cynthia M. Butitta | Grant or award | Stock Option (right to buy) | 29,500 | $0.00 | - | |
| J. Scott Garland | Grant or award | Stock Option (right to buy) | 29,500 | $0.00 | - | |
 Gorjan Hrustanovic | Grant or award | Stock Option (right to buy) | 29,500 | $0.00 | - | |
| Ian T. Clark | Grant or award | Stock Option (right to buy) | 29,500 | $0.00 | - | |
 Yi Larson | Grant or award | Stock Option (right to buy) | 29,500 | $0.00 | - | |
| Sandra Horning | Grant or award | Stock Option (right to buy) | 29,500 | $0.00 | - | |
| Prakash Raman | Grant or award | Stock Option (right to buy) | 29,500 | $0.00 | - | |
| Andrew Rappaport | Grant or award | Stock Option (right to buy) | 29,500 | $0.00 | - | |
 G. Walmsley Graham | Grant or award | Stock Option (right to buy) | 29,500 | $0.00 | - | |
| Prakash Raman | Grant or award | Stock Option (Right to Buy) | 2,911 | $0.00 | - | |
| Prakash Raman | Grant or award | Stock Option (Right to Buy) | 24,150 | $0.00 | - | |
| Shawnte Mitchell - Officer | Open-market sale | Common Stock | 24,767 | $24.25 footnote F2 | $601K | |
| Shawnte Mitchell - Officer | Open-market sale | Comon Stock | 233 | $24.69 footnote F3 | $6K | |
| Shawnte Mitchell - Officer | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Shawnte Mitchell - Officer | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Shawnte Mitchell - Officer | Option exercise | Common Stock | 15,000 | $4.37 | $66K | |
| Shawnte Mitchell - Officer | Option exercise | Common Stock | 25,000 | $4.37 | $109K | |
| Shawnte Mitchell - Officer | Open-market sale | Common Stock | 15,000 | $23.01 footnote F1 | $345K | |
| ||||||
 Sasha Lu Austin - Officer | Grant or award | Common Stock | 11,700 | $0.00 | - | |
| Sasha Lu Austin - Officer | Grant or award | Stock Option (Right to Buy) | 29,250 | $0.00 | - | |
| Naseem Zojwalla - Officer | Grant or award | Stock Option (Right to Buy) | 250,000 | $0.00 | - | |
| Naseem Zojwalla - Officer | Grant or award | Performance Stock Options (Right to Buy) | 106,250 | $0.00 | - | |
| David C. Myles - Officer | Grant or award | Stock Option (Right to Buy) | 250,000 | $0.00 | - | |
| David C. Myles - Officer | Grant or award | Performance Stock Options (Right to Buy) | 106,250 | $0.00 | - | |
| Shawnte Mitchell - Officer | Grant or award | Stock Option (Right to Buy) | 220,000 | $0.00 | - | |
| Shawnte Mitchell - Officer | Grant or award | Performance Stock Options (Right to Buy) | 56,250 | $0.00 | - | |
| Sean Bohen - Officer | Grant or award | Stock Option (Right to Buy) | 850,000 | $0.00 | - | |
| Sean Bohen - Officer | Grant or award | Performance Stock Options (Right to Buy) | 275,000 | $0.00 | - | |
| Cyrus Harmon | Open-market sale | Common Stock | 10,000 | $26.88 footnote F1 | $269K | |
| ||||||
| Cyrus Harmon | Open-market sale | Common Stock | 3,489 | $29.12 footnote F1 | $102K | |
| ||||||
| Shane William Charles Kovacs - Officer | Open-market sale | Common Stock | 3,822 | $28.01 footnote F1 | $107K | |
| Shane William Charles Kovacs - Officer | Open-market sale | Common Stock | 100,000 | $28.73 footnote F2 | $2.87M | |
| ||||||
| David C. Myles - Officer | Open-market sale | Common Stock | 200 | $28.49 | $6K | |
| David C. Myles - Officer | Option exercise | Common Stock | 50,000 | $4.87 | $244K | |
| David C. Myles - Officer | Open-market sale | Common Stock | 10,000 | $28.34 footnote F1 | $283K | |
| David C. Myles - Officer | Option exercise | Common Stock | 50,000 | $4.87 | $244K | |
| David C. Myles - Officer | Open-market sale | Common Stock | 49,800 | $27.60 footnote F4 | $1.37M | |
| David C. Myles - Officer | Open-market sale | Common Stock | 14,997 | $28.60 footnote F5 | $429K | |
| David C. Myles - Officer | Open-market sale | Common Stock | 35,003 | $28.99 footnote F6 | $1.01M | |
| David C. Myles - Officer | Option exercise | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| David C. Myles - Officer | Option exercise | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| ||||||
| Shane William Charles Kovacs - Officer | Gift | Common Stock | 225,000 | $0.00 | - | |
| Andrew Rappaport | Option exercise | Common Stock | 35,868 | $0.39 | $14K | |
| Andrew Rappaport | Gift | Common Stock | 35,868 | $0.00 | - | |
| Andrew Rappaport | Option exercise | Stock Option (right to buy) | 35,868 | $0.00 | - | |
| Cyrus Harmon | Open-market sale | Common Stock | 10,000 | $8.04 | $80K | |
| Cyrus Harmon | Open-market sale | Common Stock | 10,000 | $8.33 | $83K | |
| Cyrus Harmon | Open-market sale | Common Stock | 1,914 | $8.08 | $15K | |
| Cyrus Harmon | Open-market sale | Common Stock | 3,086 | $8.32 | $26K | |
| Cynthia M. Butitta | Grant or award | Stock Option (right to buy) | 24,150 | $0.00 | - | |
| Andrew Rappaport | Grant or award | Stock Option (right to buy) | 24,150 | $0.00 | - | |
| BVF PARTNERS L P - Director | Grant or award | Stock Option (Right to buy) | 24,150 | $0.00 | - | |
Item 5.02, 7.01, 9.01
Item 2.02, 9.01
Item 5.07
Item 7.01, 8.01, 9.01
Recent OLMA Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
OLMA insider trading FAQ
What is the latest insider trade for OLMA?
Olema Pharmaceuticals, Inc. (OLMA) had 2 insider filings in the last 90 days, with the most recent on 2026-09-02. The full record for OLMA runs to 39 Form 4 filings, the earliest from 2024-11-18. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying OLMA stock?
No insider purchases of OLMA were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling OLMA stock?
2 insider sales of OLMA were filed in the last 90 days, totaling $291K.
Where can I see OLMA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects OLMA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Jason O'Byrne view on EDGAR
- - Cyrus Harmon view on EDGAR
- - BVF PARTNERS L P view on EDGAR
- - Cyrus Harmon view on EDGAR
- - Cynthia M. Butitta view on EDGAR
- - J. Scott Garland view on EDGAR
- - Gorjan Hrustanovic view on EDGAR
- - Ian T. Clark view on EDGAR
- - Yi Larson view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where OLMA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow OLMA with a 7-day demo
- OLMA on your watchlist
- Every OLMA Form 4 filing on record
- Up to 3 months of OLMA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
